Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by DJDawgon Jul 27, 2021 3:51pm
192 Views
Post# 33611520

screenshot question

screenshot questionRegarding the recent AGM screenshot from recently.....

- the most recent documents talk about the 7 optimized Primary and then the 11 that go a do-over with an optimized "Maintenance" treatment. I'm assuming that for those of the 11 that were grossly underdosed before, this optimized treatment would be kind of like a first real treatment.
- if so, how do we see them in the screenshot? One would assume it would show as PR patients jumping into the CR group count. Or NR patients jumpting into the CR or PR groupings. Which we are not seeing. I personally wonder if they 11 optimized Maintenance patients are not represented on the table at all...yet.

Incidentally, I can see why they picked 6 m for the second treatment in all comers. The CR and PR group numbers holds from 90 to 180 days and then starts losing patients. So that logic is good to see.

I've seen some pharma results where they show every patient's journey individually so you can see where they are. Wish they did that here.
<< Previous
Bullboard Posts
Next >>